Leveraging Prior Knowledge to Support Early Phase Clinical Trial Applications: Regulatory CMC Considerations and Case Studies

Prior knowledge was successfully used to support the clinical trial applications of two small interfering RNA (siRNA) investigational medicinal products (IMPs). A comparative, risk-based approach was used to introduce supportive stability data from three other siRNA IMPs to establish an initial 36 m...

Full description

Saved in:
Bibliographic Details
Published in:Organic process research & development 2023-04, Vol.27 (4), p.784-787
Main Authors: Fogh Hedegaard, Sofie, Rebecca Erritzøe Hansen, Rosa, Nelson, Robert, Kristian Klausen, Niels, Fogt Hjorth, Christian, Troup, Lori, Eskling, Marie, Storgaard, Morten, Khürshid, Saad, Roberts, Scott W.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prior knowledge was successfully used to support the clinical trial applications of two small interfering RNA (siRNA) investigational medicinal products (IMPs). A comparative, risk-based approach was used to introduce supportive stability data from three other siRNA IMPs to establish an initial 36 month drug product shelf life. The structuring of supportive data from other clinical programs into Module 3 Quality of the Common Technical Document and response from health authorities is additionally presented.
ISSN:1083-6160
1520-586X
DOI:10.1021/acs.oprd.3c00040